ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
-0.01
-0.47%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
-0.11
-0.91%
ILMN
178.47
-0.86
-0.48%
INNV
0.29
+0.01
+3.5357%
INO
9.44
-0.06
-0.63%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
0.00%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
-0.69
-1.28%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
-0.06
-1.51%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
0.00%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
ACAD
34.3
-0.68
-1.94%
AEMD
4.96
-0.15
-2.94%
APRI
0.342
-0.008
-2.3163%
ARNA
1.73
-0.01
-0.57%
ATEC
8.21
-0.42
-4.87%
CNAT
2.1
-0.01
-0.47%
CRXM
0.24
-0.03
-10.70%
CYTX
2.04
-0.08
-3.77%
DXCM
93.16
-0.75
-0.80%
GNMK
11.56
-0.14
-1.20%
HALO
11.98
-0.11
-0.91%
ILMN
178.47
-0.86
-0.48%
INNV
0.29
+0.01
+3.5357%
INO
9.44
-0.06
-0.63%
ISCO
1.84
-0.06
-3.16%
ISIS
57.56
0.00
0.00%
LGND
113.09
-2.69
-2.32%
LPTN
3.83
-0.06
-1.54%
MBVX
4.16
-0.56
-11.86%
MEIP
1.71
+0.02
+1.18%
MNOV
7.47
+0.37
+5.21%
MRTX
6.2
+0.32
+5.44%
MSTX
0.123
-0.004
-3.454%
NBIX
53.25
-0.69
-1.28%
NUVA
66.15
-0.62
-0.93%
ONCS
1.77
-0.01
-0.56%
ONVO
3.91
-0.06
-1.51%
OREX
3.24
-0.22
-6.36%
OTIC
17.13
-0.52
-2.95%
QDEL
22.17
-0.54
-2.38%
RCPT
231.96
0.00
0.00%
RGLS
3.42
-0.03
-0.87%
RMD
63.59
+0.34
+0.54%
SPHS
3.22
+0.26
+8.78%
SRNE
7.67
-0.1
-1.29%
TROV
4.63
-0.16
-3.34%
VICL
3.19
-0.06
-1.85%
VOLC
18
0.00
0.00%
ZGNX
10.35
-0.1
-0.96%
Home » Archive by Category

Xconomy

Bio Roundup: FDA Says No, PCSK9 Value Fight, CRISPR Intrigue & More

August 19, 2016 – 3:30 am

When the Olympics roll around, many watchers get into a sport they previously hadn’t thought much about. This time for me, it’s volleyball. The men’s and women’s games, both…

[[Click headline to continue reading.]]

Avelas Bio Raises $20M to Push Cancer-Illuminating Biologic Agent

August 17, 2016 – 9:01 pm

San Diego’s Avelas Biosciences, founded in 2009 to advance a fluorescing biologic agent intended to help surgeons differentiate cancerous tissue from healthy tissue, has completed a $20 million…

[[Click headline to continue reading.]]

With $6M Investment, Histogen Aims to Grow Hair Business in China

August 17, 2016 – 10:38 am

Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a…

[[Click headline to continue reading.]]

Pharma’s Productivity Problem: Finding More Blockbuster Drugs

August 16, 2016 – 10:19 pm

A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the…

[[Click headline to continue reading.]]

Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More

August 12, 2016 – 6:23 am

The wait continues. An FDA ruling on a Duchenne muscular dystrophy drug from Sarepta Therapeutics—which could be the first ever approved for the disease—has been imminent for a while now,…

[[Click headline to continue reading.]]

As U.S. Looks to Launch Precision Health Study, Google’s Role Emerges

August 11, 2016 – 2:00 am

The U.S. government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of…

[[Click headline to continue reading.]]

MEI Pharma Partners with Helsinn on Drug with Potential $464M Payoff

August 8, 2016 – 5:00 am

After reporting encouraging news last week from a mid-stage trial of its lead anti-cancer drug, San Diego’s MEI Pharma (NASDAQ: MEIP) said it has signed a drug development deal with the Swiss…

[[Click headline to continue reading.]]

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

August 5, 2016 – 4:04 am

Biogen was once again all over the biotech newswire this week. First came a positive surprise; data that could set the stage for the first-ever drug approved for spinal muscular atrophy, a rare and…

[[Click headline to continue reading.]]

Look Beyond Football to Fight Concussions

August 2, 2016 – 8:44 am

The New York Times reported last week that the NFL and USA Football had publicized inaccurate statistics about the efficacy of a training program called Heads Up Football in preventing concussions in…

[[Click headline to continue reading.]]

Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing

August 1, 2016 – 6:07 am

Spinal muscular atrophy affects over 25,000 people in the U.S. and stops many of them from ever being able to walk. Yet scientists’ understanding of the underlying genetic cause of SMA is…

[[Click headline to continue reading.]]